Zhu Li-Ping, Xing Jing, Wang Qing-Xiao, Kou Lei, Li Chen, Hu Bi, Wu Zhi-Wei, Wang Jian-Jun, Xu Gen-Xing
Department of Biological Science and Technology and State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.
Eur J Pharmacol. 2009 Sep 1;617(1-3):23-7. doi: 10.1016/j.ejphar.2009.07.003. Epub 2009 Jul 16.
Endostatin is an endogenous inhibitor of angiogenesis and has been shown to exhibit potent inhibitory activity in certain mice tumor models. In this study, a treatment strategy of combining recombinant human endostatin (rhEndostatin) and chemotherapeutics was implemented to evaluate the therapeutic efficacy of rhEndostatin against solid tumors. The antitumor effect of rhEndostatin in combination with several chemotherapeutic drugs, e.g., 5-fluorouracil, cyclophosphamide, methotrexate, and mitomycin C, on human QGY liver tumor and mice H22 liver tumor was compared with that of rhEndostatin treatment alone. The results showed that the combination of rhEndostatin and chemotherapeutic drugs resulted in a more potent inhibition of tumor growth. The potential advantages of rhEndostatin plus tumor chemotherapy provide a basis for further clinical trials of rhEndostatin.
内皮抑素是一种内源性血管生成抑制剂，在某些小鼠肿瘤模型中已显示出强大的抑制活性。在本研究中，实施了一种将重组人内皮抑素（rhEndostatin）与化疗药物相结合的治疗策略，以评估rhEndostatin对实体瘤的治疗效果。将rhEndostatin与几种化疗药物（如5-氟尿嘧啶、环磷酰胺、甲氨蝶呤和丝裂霉素C）联合应用对人QGY肝癌和小鼠H22肝癌的抗肿瘤作用与单独使用rhEndostatin治疗进行了比较。结果表明，rhEndostatin与化疗药物联合使用对肿瘤生长的抑制作用更强。rhEndostatin加肿瘤化疗的潜在优势为rhEndostatin的进一步临床试验提供了依据。
